Myeloproliferative Neoplasms | Specialty

Dr. Harrison on 5-Year Follow-Up Data on Ruxolitinib in Patients With Myelofibrosis

December 6th 2015

Claire Harrison, MD, deputy clinical director of Cancer and Hematology, Guy's and St. Thomas' NHS, discusses 5-year follow-up data examining ruxolitinib in patients with myelofibrosis.

Ruxolitinib Continues to Impress in Long-Term Myelofibrosis Follow-Up

December 5th 2015

Ruxolitinib continues to demonstrate sustained benefits for patients with myelofribrosis in a 5-year follow-up of the phase III COMFORT-II study.

Dr. Ruben Mesa on Advancements in Polycythemia Vera

November 11th 2015

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses advancements in polycythemia vera (PV).

Individualizing Care for Patients With Polycythemia Vera

November 4th 2015

The landscape for the diagnosis and treatment of polycythemia vera (PV) is changing, and that's good news for patients and practitioners who can look to improvements ahead.

Imetelstat Promising Across Myeloproliferative Neoplasms

September 4th 2015

The telomerase inhibitor imetelstat has shown encouraging signs of clinical activity in patients with myelofibrosis and essential thrombocythemia.

Dr. Mesa on Intended Patients With Myelofibrosis for Pacritinib

August 14th 2015

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses the intended patient population with myelofibrosis and low platelet counts for pacritinib.

Mesa Discusses Pacritinib's Potential in Myelofibrosis

June 11th 2015

Lead PERSIST-1 author Ruben A. Mesa, MD, deputy director of the Mayo Clinic Cancer Center in Scottsdale, Arizona, discussed the trial's results and pacritinib's potential to change the treatment paradigm for patients with myelofibrosis.

Dr. Mesa on Pacritinib for Myelofibrosis

June 8th 2015

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses PERSIST-1, a phase III study which examined pacribitinib as a treatment of myelofibrosis.

Novel JAK Inhibitor Alleviates Key Myelofibrosis Symptoms

May 30th 2015

Patients with myelofibrosis achieved significantly better outcomes in spleen volume reduction and symptom control with the novel JAK2 inhibitor pacritinib compared with best available therapy.

Pacritinib Shows Promise for Spleen Reduction in Myelofibrosis

March 10th 2015

Pacritinib, a JAK2/FLT3 multikinase inhibitor, significantly reduced spleen volume for patients with myeloproliferative neoplasms when compared to non-JAK2 inhibitors.

Incyte Medical Officer Elaborates on Ruxolitinib Benefit for Polycythemia Vera

January 29th 2015

For additional insight on the published RESPONSE data and the use of ruxolitnib to treat polycythemia vera, we reached out to Richard Levy, MD, executive vice president and chief drug development and medical officer at Incyte, the company that co-manufactures ruxolitinib with Novartis.

Two Experts Discuss JAK Inhibition in Polycythemia Vera

December 11th 2014

2014 ASH Annual Meeting

December 11th 2014

RESPONSE Trial Validates Ruxolitinib in Polycythemia Vera

December 11th 2014

FDA Approves Ruxolitinib for Polycythemia Vera

December 4th 2014

The FDA has approved the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

FDA Grants Priority Review to Ruxolitinib in Polycythemia Vera

August 5th 2014

The FDA has assigned a priority review designation to the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

Ruxolitinib Outperforms Standard Therapy in Polycythemia Vera

July 24th 2014

In the first pivotal phase III study of a Janus-associated kinase (JAK) inhibitor for the treatment of polycythemia vera (PV), ruxolitinib (Jakafi) was superior to best available therapy (BAT) in maintaining control of hematocrit without the need for phlebotomy and in reducing spleen size in patients with an inadequate response to or intolerance of hydroxyurea.

Dr. Komrokji on Pacritinib for the Treatment of Myelofibrosis

April 21st 2014

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses an analysis of pacritinib for the treatment of myelofibrosis.

Ruxolitinib Improves Outcomes for Patients With Polycythemia Vera in Phase III Study

March 7th 2014

Ruxolitinib, a JAK1/2 inhibitor, is the first treatment to demonstrate efficacy in a phase III trial for patients with polycythemia vera (PV), a chronic, incurable blood cancer with limited treatment options

Dr. Tefferi on the Toxicity Profile of Imetelstat

January 23rd 2014

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the toxicity of imetelstat in patients with myelofibrosis.